Cargando…

Comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national cohort study

Statins have been recommended for use in atherosclerotic cardio-cerebrovascular disease (CCVD). The purpose of this study was to investigate the efficacy of five different types of statin in the secondary prevention of CCVD in patients. This study retrospectively designed and analyzed data from the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Joungyoun, Kim, Hyeong-Seop, Bae, Yun-Jong, Lee, Hyeong-Chul, Lee, Jae-woo, Kang, Hee-Taik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906327/
https://www.ncbi.nlm.nih.gov/pubmed/33630898
http://dx.doi.org/10.1371/journal.pone.0247419
_version_ 1783655265268137984
author Kim, Joungyoun
Kim, Hyeong-Seop
Bae, Yun-Jong
Lee, Hyeong-Chul
Lee, Jae-woo
Kang, Hee-Taik
author_facet Kim, Joungyoun
Kim, Hyeong-Seop
Bae, Yun-Jong
Lee, Hyeong-Chul
Lee, Jae-woo
Kang, Hee-Taik
author_sort Kim, Joungyoun
collection PubMed
description Statins have been recommended for use in atherosclerotic cardio-cerebrovascular disease (CCVD). The purpose of this study was to investigate the efficacy of five different types of statin in the secondary prevention of CCVD in patients. This study retrospectively designed and analyzed data from the National Health Insurance Service-National Health in Korea. Participants aged 40 to 69 years were categorized into five statin groups (atorvastatin, rosuvastatin, pitavastatin, simvastatin, and pravastatin). The primary composite outcome was defined as recurrence of CCVD or all causes of death. Cox proportional hazard regression models were adopted after stepwise adjustments for confounders to investigate the difference in efficacy among the different statins. Of the 755 final participants, 48 patients experienced primary composite outcomes. After adjustments, the hazard ratios (95% confidence intervals) for primary composite outcomes of atorvastatin, pitavastatin, and rosuvastatin groups were 0.956 (0.456–2.005), 1.347 (0.354–5.116), and 0.943 (0.317–2.803), respectively, when compared with the simvastatin group. There were no significant differences between the statins in efficacy for preventing recurrence of CCVD events and/or death in CCVD patients.
format Online
Article
Text
id pubmed-7906327
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-79063272021-03-03 Comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national cohort study Kim, Joungyoun Kim, Hyeong-Seop Bae, Yun-Jong Lee, Hyeong-Chul Lee, Jae-woo Kang, Hee-Taik PLoS One Research Article Statins have been recommended for use in atherosclerotic cardio-cerebrovascular disease (CCVD). The purpose of this study was to investigate the efficacy of five different types of statin in the secondary prevention of CCVD in patients. This study retrospectively designed and analyzed data from the National Health Insurance Service-National Health in Korea. Participants aged 40 to 69 years were categorized into five statin groups (atorvastatin, rosuvastatin, pitavastatin, simvastatin, and pravastatin). The primary composite outcome was defined as recurrence of CCVD or all causes of death. Cox proportional hazard regression models were adopted after stepwise adjustments for confounders to investigate the difference in efficacy among the different statins. Of the 755 final participants, 48 patients experienced primary composite outcomes. After adjustments, the hazard ratios (95% confidence intervals) for primary composite outcomes of atorvastatin, pitavastatin, and rosuvastatin groups were 0.956 (0.456–2.005), 1.347 (0.354–5.116), and 0.943 (0.317–2.803), respectively, when compared with the simvastatin group. There were no significant differences between the statins in efficacy for preventing recurrence of CCVD events and/or death in CCVD patients. Public Library of Science 2021-02-25 /pmc/articles/PMC7906327/ /pubmed/33630898 http://dx.doi.org/10.1371/journal.pone.0247419 Text en © 2021 Kim et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Kim, Joungyoun
Kim, Hyeong-Seop
Bae, Yun-Jong
Lee, Hyeong-Chul
Lee, Jae-woo
Kang, Hee-Taik
Comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national cohort study
title Comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national cohort study
title_full Comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national cohort study
title_fullStr Comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national cohort study
title_full_unstemmed Comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national cohort study
title_short Comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national cohort study
title_sort comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7906327/
https://www.ncbi.nlm.nih.gov/pubmed/33630898
http://dx.doi.org/10.1371/journal.pone.0247419
work_keys_str_mv AT kimjoungyoun comparingdifferenttypesofstatinsforsecondarypreventionofcardiocerebrovasculardiseasefromanationalcohortstudy
AT kimhyeongseop comparingdifferenttypesofstatinsforsecondarypreventionofcardiocerebrovasculardiseasefromanationalcohortstudy
AT baeyunjong comparingdifferenttypesofstatinsforsecondarypreventionofcardiocerebrovasculardiseasefromanationalcohortstudy
AT leehyeongchul comparingdifferenttypesofstatinsforsecondarypreventionofcardiocerebrovasculardiseasefromanationalcohortstudy
AT leejaewoo comparingdifferenttypesofstatinsforsecondarypreventionofcardiocerebrovasculardiseasefromanationalcohortstudy
AT kangheetaik comparingdifferenttypesofstatinsforsecondarypreventionofcardiocerebrovasculardiseasefromanationalcohortstudy